In the replicate phase 3 OBERON and TITANIA trials, add-on tozorakimab 300 mg every 4 weeks significantly reduced annualized moderate or severe chronic obstructive pulmonary disease exacerbation rates...
A pooled analysis of two phase 3 ENHANCE trials evaluated whether the inhaled dual phosphodiesterase 3 and 4 inhibitor antifeminine reduces chronic obstructive pulmonary disease exacerbation frequency and...
A new national analysis provides clinicians with evidence on how chronic obstructive pulmonary disease affects post-discharge outcomes in adults with sickle cell disease hospitalized for acute chest...
A nationwide Belgian cohort study found that biologic therapy targeting interleukin (IL) 5 reduced moderate and severe exacerbations among adults with severe eosinophilic asthma, including those with...
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality, but it’s also highly manageable with early recognition, evidence-based treatment, and coordinated care. This guide...
A randomized trial demonstrated that telemedicine follow-up after COPD exacerbation improved symptom scores and inhaler technique compared with standard face-to-face care, supporting its role as a safe and...
A randomized trial in moderate chronic obstructive pulmonary disease demonstrated that chest mobility exercises led to greater improvements in lung function and functional capacity compared with...
A multicenter retrospective cohort study across the Yale-New Haven Health System found that embedding a 2-part electronic health record–based care pathway for patients hospitalized with chronic obstructive...
Patients with chronic obstructive pulmonary disease who recovered from COVID-19 had nearly double the risk of long-term mortality compared with matched controls, with the highest risk observed in severe...
